Valuation: AstraZeneca PLC

Market Cap 254B 223B 210B 192B 360B 24,392B 363B 2,523B 978B 12,436B 955B 934B 40,370B P/E 2026 *
20.9x
P/E 2027 * 18.2x
Enterprise Value 274B 241B 227B 207B 387B 26,281B 391B 2,718B 1,054B 13,399B 1,028B 1,006B 43,497B EV / Sales 2026 *
4.34x
EV / Sales 2027 * 3.97x
Free-Float
96.62%
Yield 2026 *
2.04%
Yield 2027 * 2.16%
1 day+0.75%
Current month+77.38%
Current year+79.01%
Current year 89.04
Extreme 89.04
166.25
1 year 72.9
Extreme 72.895
166.25
3 years 60.47
Extreme 60.47
166.25
5 years 52.65
Extreme 52.65
166.25
10 years 25.55
Extreme 25.55
166.25
Manager TitleAgeSince
Chief Executive Officer 66 2012-09-30
Director of Finance/CFO 52 2021-07-31
Compliance Officer - 2022-12-31
Director TitleAgeSince
Director/Board Member 70 1999-04-05
Director/Board Member 66 2012-09-30
Director/Board Member 65 2017-04-26
Change 5-day change 1-year change 3-year change Capi.($)
+0.75%+0.27% - - 256B
+2.68%+3.87%+58.22%+114.68% 1,026B
+0.56%+1.27%+53.29%+68.65% 649B
+0.02%+0.99%+19.10%+73.58% 468B
+0.06%+0.25%+37.03%+45.71% 352B
+1.16%+4.10%+21.99%+29.39% 271B
-0.24%+2.18%+10.14%+12.26% 256B
-0.01%+7.89%+41.57%+51.68% 220B
-1.11%+1.36%+30.85%+99.56% 188B
+0.30%-7.19%-32.43%-60.56% 170B
Average +0.23%+1.26%+26.64%+48.33% 399.9B
Weighted average by Cap. +0.33%+1.26%+37.30%+67.68%

Financials

2026 *2027 *
Net sales 63.17B 55.52B 52.3B 47.8B 89.34B 6,060B 90.12B 627B 243B 3,090B 237B 232B 10,030B 67.01B 58.9B 55.48B 50.71B 94.78B 6,429B 95.61B 665B 258B 3,278B 252B 246B 10,641B
Net income 12.04B 10.59B 9.97B 9.11B 17.03B 1,156B 17.18B 120B 46.34B 589B 45.22B 44.23B 1,912B 13.77B 12.11B 11.4B 10.42B 19.48B 1,321B 19.65B 137B 53B 674B 51.71B 50.58B 2,187B
Net Debt 19.69B 17.31B 16.31B 14.9B 27.86B 1,890B 28.1B 195B 75.78B 963B 73.94B 72.33B 3,127B 11.93B 10.49B 9.88B 9.03B 16.87B 1,145B 17.02B 118B 45.91B 584B 44.8B 43.82B 1,895B
Logo AstraZeneca PLC
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (99.8%). Net sales break down by treatment area between oncology (42.6%), cardiovascular, renal and metabolic diseases (23%), respiratory and autoimmune diseases (14.7%), and other (19.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (0.2). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (22.9%), the United States (40.8%), Americas (6.1%) and Africa/Asia/Australia (22.8%).
Employees
96,100
Date Price Change Volume
26-09-24 $164.56 +0.75% 3,188,583
26-09-23 $163.33 -2.99% 2,361,340
26-09-22 $168.37 +0.16% 2,306,261
26-09-21 $168.10 +1.22% 2,937,798
26-09-18 $166.08 -0.04% 3,060,378
Trader
Investor
Global
Quality
ESG MSCI
-

Quarterly revenue - Rate of surprise